Accelerating Access to Cell Therapy
For Biotechs
acCELLapy understands the challenge biotechs face in ensuring life-saving and enhancing Cell Therapy products reach patients in need. Through a network of relationships with Cell Therapy programs and customized tools to efficiently assess the opportunity at new sites, acCELLapy supports biotechs expand access and improve communications with clinical leaders.
Site Recruitment
Through proprietary models and a growing network of cancer providers across the United States, acCELLapy is positioned to efficiently identify new Cell Therapy program sites and facilitate the provision of biotech therapies into established Cell Therapy programs. With an in-depth understanding of the capabilities of its provider clients and many trust based relationships in place, acCELLapy can help biotechs rapidly expand access.
Incremental Therapy Adoption and Deployment
New therapies are rapidly advancing, requiring biotechs continually educate and support Cell Therapy providers to safely deliver new therapies and identify appropriate patients for clinical trials. Through ongoing support relationships with Cell Therapy sites, acCELLapy is able to efficiently identify capability gaps for new therapies and provide – in collaboration with biotechs – incremental education and training provided.
Product Ordering
Errors with product ordering can cause supply chain issues and delay therapies reaching patients, creating increased cost and an unnecessary burden to patients. By supporting sites manage ordering through a co-management agreement, acCELLapy reduces issues, creates efficiencies of scale and reduces time to treatment.